Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients
Portfolio Pulse from Vandana Singh
Vor Biopharma presented updated data from the VBP101 Phase 1/2a study of trem-cel in acute myeloid leukemia patients, showing early encouraging results. The FDA also cleared the company's IND application for VCAR33ALLO, a T-cell therapy derived from allogeneic healthy donors.
June 09, 2023 | 6:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vor Biopharma's trem-cel shows early positive results in leukemia patients, and the FDA cleared the company's IND application for VCAR33ALLO.
The early encouraging data from the VBP101 Phase 1/2a study of trem-cel in acute myeloid leukemia patients indicates potential for the treatment's success. Additionally, the FDA clearance of the IND application for VCAR33ALLO, a T-cell therapy, further supports the company's progress in developing new treatments. Both of these factors are likely to have a positive short-term impact on Vor Biopharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100